Viking Therapeutics Announces $500M Public Offering
Viking Therapeutics (VKTX) has priced a public offering of 7.85 million shares at $35 per share, raising approximately $274.75 million in equity financing. The company is also issuing $225 million in convertible senior notes with an interest rate of 2.00%, maturing in 2032. The combined offering totals around $500 million and aims to provide Viking Therapeutics with additional capital for its operations, including research and development activities related to its drug candidates targeting metabolic diseases such as non-alcoholic steatohepatitis (NASH) and other conditions. The financing is expected to strengthen the company's balance sheet. The offering reflects investor confidence in Viking’s pipeline of therapies and could support future clinical trials or potential partnerships.
Tickers: $VKTX